Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Express Scripts
Boehringer Ingelheim
Medtronic
Johnson and Johnson

Last Updated: December 2, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 212950


Email this page to a colleague

« Back to Dashboard

NDA 212950 describes RUKOBIA, which is a drug marketed by Viiv Hlthcare and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the RUKOBIA profile page.

The generic ingredient in RUKOBIA is fostemsavir tromethamine. One supplier is listed for this compound. Additional details are available on the fostemsavir tromethamine profile page.
Summary for 212950
Tradename:RUKOBIA
Applicant:Viiv Hlthcare
Ingredient:fostemsavir tromethamine
Patents:3
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 212950
Generic Entry Date for 212950*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET, EXTENDED RELEASE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 212950
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RUKOBIA fostemsavir tromethamine TABLET, EXTENDED RELEASE;ORAL 212950 NDA ViiV Healthcare Company 49702-250 49702-250-18 1 BOTTLE in 1 CARTON (49702-250-18) > 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 600MG BASE
Approval Date:Jul 2, 2020TE:RLD:Yes
Regulatory Exclusivity Expiration:Jul 2, 2025
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:⤷  Free Forever TrialPatent Expiration:Nov 19, 2027Product Flag?Substance Flag?YDelist Request?
Patent:⤷  Free Forever TrialPatent Expiration:Feb 25, 2025Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Medtronic
McKinsey
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.